An educational R&D day
Destiny recently held a R&D Day and the presentations on its two Phase 3-ready products from key opinion leaders and Destiny’s senior team effectively burnished the profile of the products, probably for the benefit of potential licensees. The schedule of hoped-for licensing transactions was laid out, with M3 targeted this year and XF-73 in 2023. They also reiterated that Phase 3 studies will not start without the support of partners.Destiny’s lead Phase 3-ready product is the non-toxigenic Clostridioides difficile strain M3 (NTCD-M3) for the prevention of C.difficile infections (CDI’s). Professor Wilcox of Leeds University school of medicine outlined not just the significant unmet medical need of CDIs and the increasing incidence because of aging populations, but also a perspective on drug regulators and the competition to M3.
Earlier in the year, Destiny’s discussions with regulators resulted in a proposal for the Phase 3 study of XF-73 in the prevention of post-surgical staphylococcal infections to be conducted in breast reconstruction procedures in cancer patients. The presentation given by Dr Alex Mericli, a leading plastic surgeon at the MD Anderson Cancer Center in Texas, highlighted this large and easily accessible market.
We ascribe an unchanged fair value to Destiny Pharma of £251.2m or 345p per share.
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.